Ranbaxy Laboratories Ltd.'s, India's biggest drug producer, wants revenue growth in Europe, Africa and the Commonwealth of Independent States during the next three years.
1. It made at least eight acquisitions since January 2006, half of them in Europe and South Africa, to cut distribution costs and spur sales of generic medicines.
2. It will spend about 100 million rand ($14 million) to upgrade the Be-Tabs Pharmaceuticals (Pty) Ltd. plant in South Africa it bought for 500 million rand last year. The facility will eventually produce Ranbaxy's anti-AIDS drugs for the South African market and may supply other products to its international operations.
“Go forth and multiply” has taken on a whole new meaning.
[Click here for full story at: BLOOMBERG.COM]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment